China is a large country with hepatitis B. The number of hepatitis B cases ranks first in the statutory management of infectious diseases. When the patient itself has hepatitis B and rheumatism at the same time, we should be more careful to choose the treatment drugs and in the treatment of rheumatism need to do a good job of self-monitoring hepatitis B whether there is viral replication activity. 1, liver function and hepatitis B virus quantification are normal: can take normal anti-rheumatic drugs. 2, liver function suggests that the transaminases are abnormal, but the viral quantification is normal: when the transaminase level is higher than the normal value on the line two times, should be prohibited or stopped to flumet, methotrexate, lorazepam, which does not include biological agents. 3, hepatitis patients with abnormal viral quantification: liver transaminase level higher than 2 times the upper limit of normal is not a contraindication to the application of TNF antagonists, for acute hepatitis B virus infection, as well as those with significant liver damage, should check the hepatitis B virus quantification, if the hepatitis B virus quantification > 104, it is recommended to first antiviral treatment, to be used after the virus quantification < 1000, biological agents will be safer. 4. For patients using biological agents, it is recommended to review liver function and hepatitis B virus quantification every month, liver ultrasound every 6 months, and tumor markers such as AFP and CEA every 6 months. 5, patients with hepatitis B rheumatism is not recommended to pursue the complete remission of rheumatism, this part of the patient's treatment should find a balance, that is, can control the activity of rheumatism, but also do not let the hepatitis B virus replication, which is a win-win treatment strategy.